Intec Pharma (NASDAQ:NTEC) PT Set at $16.00 by HC Wainwright

Intec Pharma (NASDAQ:NTEC) received a $16.00 price target from equities research analysts at HC Wainwright in a research note issued on Thursday, June 20th, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 311.31% from the stock’s previous close.

A number of other research firms have also recently commented on NTEC. ValuEngine upgraded shares of WPP from a “sell” rating to a “hold” rating in a report on Wednesday, June 19th. Maxim Group reiterated a “buy” rating and set a $12.00 target price on shares of Intec Pharma in a report on Thursday, June 20th. BidaskClub upgraded shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 6th. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a report on Friday, February 22nd. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $15.00 target price on shares of Intec Pharma in a report on Thursday, June 20th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $12.17.

Shares of NTEC stock traded down $0.10 during mid-day trading on Thursday, hitting $3.89. The company had a trading volume of 272,363 shares, compared to its average volume of 460,217. The stock has a market capitalization of $130.98 million, a P/E ratio of -2.78 and a beta of 0.28. The company has a 50 day simple moving average of $4.60. Intec Pharma has a 52-week low of $3.55 and a 52-week high of $9.25.

Intec Pharma (NASDAQ:NTEC) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.05. As a group, sell-side analysts anticipate that Intec Pharma will post -1.05 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of NTEC. PRW Wealth Management LLC acquired a new stake in shares of Intec Pharma during the 4th quarter worth approximately $29,000. BlackRock Inc. acquired a new stake in shares of Intec Pharma during the 4th quarter worth approximately $67,000. Marshall Wace North America L.P. acquired a new stake in shares of Intec Pharma during the 1st quarter worth approximately $117,000. Delek Group Ltd. acquired a new stake in shares of Intec Pharma during the 1st quarter worth approximately $154,000. Finally, Sigma Planning Corp acquired a new stake in shares of Intec Pharma during the 1st quarter worth approximately $183,000. 33.64% of the stock is owned by institutional investors.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Article: What are catch-up contributions?

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.